9363 Towne Centre Drive
184 articles with Mirati Therapeutics
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference, which will be webcast on June 9.
Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China
- Zai Lab obtains the right to develop and exclusively commercialize adagrasib in China, Hong Kong, Macau and Taiwan - Mirati to receive an upfront payment of $65 million, up to approximately $273 million in potential milestone payments and high-teen- to low-twenties-percent tiered royalties - Agreement will accelerate enrollment in key global, registration-enabling clinical trials investigating adagrasib in patients with KRAS G12C mutations
Initiated potentially registration-enabling trials evaluating our investigational KRASG12C inhibitor, adagrasib, in lung and colorectal cancers, as monotherapy and with other agents
Stand Up To Cancer Announces $4 Million Grant From Mirati Therapeutics To Support Research On KRAS Mutant Cancers
Stand Up To Cancer® and Mirati Therapeutics Inc. – a late-stage targeted oncology company – announced that Mirati will contribute a $4 million grant to SU2C to develop new approaches to treat patients with KRAS mutant cancers, as a part of the SU2C Catalyst® program.
Mirati Therapeutics Presents Preclinical Data on Novel Approach to PRMT5 Inhibition that Selectively Targets the PRMT5/MTA Complex in MTAP-Deleted Cancer Models
Internally discovered PRMT5 program represents a potential first-in-class approach to specifically target MTAP-deleted tumors Anticipate filing an Investigational New Drug application in the first half of 2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced its Board of Directors has elected a new independent director, Ms. Shalini Sharp .
Mirati Therapeutics to Present Late-Breaking Data That Advance the Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP-Deleted Cancers at AACR 2021
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced it will present initial preclinical data on the Company's synthetic lethal PRMT5 inhibitor during a late-breaking minisymposium at the American Association for Cancer Research (AACR) Virtual Annual Meeting taking place April 10-15, 2021.
Mirati Therapeutics, Inc., a late-stage targeted oncology company, will participate in two upcoming healthcare conferences.
MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced a strategic research and development collaboration to expand the evaluation of Mirati's two investigational small molecule, potent and selective KRAS inhibitors
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced they will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Days on Thursday, February 11 th at 9:00 a.m. ET / 6:00 a.m. PT
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 39th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 11 th at 12:40 p.m. PST / 3:40 p.m. EST . Charles M. Baum , M.D., Ph.D., Mirati's President and Chief Executive Officer will present at the con
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 2020 Evercore ISI HealthCONx Conference on Tuesday, December 1st at 8:20 a.m. PT/11:20 a.m. ET. Dan Faga, Executive Vice President and Chief Operating Officer, will represent Mirati at the event.
Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, announced they will participate in a fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Thursday, November 12, 2020 at 9:30 a.m. PT/12:30 p.m. ET.
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2020 and recent business highlights.
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares - Oct 30, 2020
Mirati Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 4,985,706 shares of its common stock at a public offering price of $202.00 per share, which consists of 4,585,706 shares sold by Mirati and 400,000 shares sold by a selling stockholder.
Mirati Therapeutics, Inc. announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to the public of $202.00 per share, which consists of 3,960,397 shares to be sold by Mirati and 375,000 shares to be sold by a selling stockholder.
Mirati Therapeutics, Inc. announced that it intends to offer and sell in an underwritten public offering $700.0 million of shares of its common stock and a selling stockholder intends to offer 375,000 shares in the offering.
Mirati Therapeutics Reports Investigational Adagrasib (MRTX849) Preliminary Data Demonstrating Tolerability and Durable Anti-Tumor Activity as well as Initial MRTX1133 Preclinical Data
45% confirmed ORR and 96% DCR across Phase 1/1b and Phase 2 monotherapy cohorts in patients with advanced NSCLC
Mirati Therapeutics To Present Data During The 2020 EORTC-NCI-AACR International Virtual Conference On Molecular Targets And Therapeutics (ENA)
- Updated adagrasib (MRTX849) clinical data in non-small cell lung cancer (NSCLC) patients will be featured in a plenary session at ENA - Updated adagrasib clinical data in colorectal cancer (CRC) and other KRAS G12C positive solid tumors outside of NSCLC will be presented in a second session at ENA - Mirati to host virtual investor event on October 25th to discuss adagrasib clinical data presented at ENA and provide an update on MRTX1133, the Company's KRAS G12D selective in
San Diego-based Mirati Therapeutics, a clinical-stage biotechnology company, is currently developing sitravatinib to address unmet medical needs in cancer care.